Skip to main content

Houlihan Capital

Cannabis Rescheduling Is Here. What It Means for Business Valuations.

Banner image for Houlihan Capital about cannabis rescheduling and business valuations, featuring cannabis leaves and a dark overlay with the headline text.

On April 22, 2026, the Acting Attorney General issued a final order reclassifying FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act. A formal DEA hearing on broader cannabis rescheduling is scheduled to begin June 29, 2026.  This is the most consequential shift in federal marijuana […]